Chugai Pharmaceutical (4519.T) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $70.70B | Exchange | JPX |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | JP | CEO | Osamu Okuda |
| IPO Date | 1956-03-02 | CAGR | 7.97% |
| Employees | 5,104 | Website | www.chugai-pharm.co.jp |
| Div. Yield | 6.01% | Payout Ratio | 95% |
| Buy Back Yield | 0.03% | Total Yield | 6.04% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $69.50B | P/E | 23.88 | Forward P/E | — | PEG | 1.21 |
| P/S | 4.33 | P/B | 2.86 | P/CF | 12.81 | P/FCF | 14.36 |
| Sales | $8.20B | Sales 1Y | 12.25% | Sales 3Y | 7.99% | Sales 5Y | 65.97% |
| EPS | $1.8 | EPS 1Y | 19.2% | EPS 3Y | 44.14% | EPS 5Y | 104.29% |
| Sales QoQ | 6.17% | EPS QoQ | 0.8% | Sales QoQ Avg | 4.48% | EPS QoQ Avg | 5.15% |
| Gross Margin | 71.39% | Operating Margin | 47.24% | Profit Margin | 35.1% | ROCE | 30.83% |
| ROA | 19% | ROE | 24% | Altman Z Score | 20.47 | Piotroski Score | 6 |
| Current Ratio | 4.35 | Quick Ratio | 3.54 | Cash Ratio | 1 | Op. CF Ratio | 0.33 |
| Debt/Equity | — | Debt/Assets | — | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | 652.57 | Inventory Turnover | 1.21 | Asset Turnover | 0.55 | Receivables Turnover | 3.52 |
| Enterprise Value | $69.50B | P/E Ratio | 23.88 |
| Forward P/E | — | PEG Ratio | 1.21 |
| P/S Ratio | 4.33 | P/B Ratio | 2.86 |
| P/CF Ratio | 12.81 | P/FCF Ratio | 14.36 |
| EPS | $1.8 | EPS Growth 1Y | 19.2% |
| EPS Growth 3Y | 44.14% | EPS Growth 5Y | 104.29% |
| Revenue Growth 1Y | 12.25% | Gross Margin | 0.71% |
| Operating Margin | 0.47% | Profit Margin | 0.35% |
| ROE | 0.24% | ROA | 0.19% |
| ROCE | 0.31% | Current Ratio | 4.35 |
| Quick Ratio | 3.54 | Cash Ratio | 1 |
| Debt/Equity | — | Interest Coverage | 652.57 |
| Altman Z Score | 20.47 | Piotroski Score | 6 |
Chugai Pharmaceutical (4519.T) valuation & financials
Chugai Pharmaceutical (4519.T) has a market capitalization of 70.70B JPY and trades at a price-to-earnings ratio of 23.9. It operates in the Healthcare sector (Drug Manufacturers - General).
Chugai Pharmaceutical's revenue grew +12.3% over the last year.
Chugai Pharmaceutical's next earnings report is scheduled for October 27, 2026; analysts estimate EPS of 0.48 JPY. Check the earnings calendar to see all companies reporting this week.
Chugai Pharmaceutical (4519.T) — frequently asked questions
When does Chugai Pharmaceutical (4519.T) report earnings next?
Chugai Pharmaceutical is expected to report earnings on October 27, 2026. Analysts estimate EPS of 0.48 JPY.
What is Chugai Pharmaceutical's market cap?
Chugai Pharmaceutical (4519.T) has a market capitalization of 70.70B JPY.
What is 4519.T's P/E ratio?
Chugai Pharmaceutical trades at a price-to-earnings ratio of 23.9, with trailing twelve-month EPS of 1.80 JPY.
How fast is Chugai Pharmaceutical growing?
Chugai Pharmaceutical's revenue grew +12.3% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)